Neosoma Brain Mets
FDA Cleared and fully-integrated with Neosoma's proprietary cloud platform, with novel mets-specific interfaces, reports, and capabilities, Neosoma Brain Mets is a new paradigm in the efficient assessment and auto-contouring of metastatic brain lesions for the entire multidisciplinary team.

Lesion Tracking At Your Fingertips
Brain metastases assessment requires additional quantitative information in the form of lesion-level insights. Neosoma quantifies and measures not only total tumor burden, but also each individual lesion, at each timepoint, and over time.

Speed and Performance: Pick Two
Neosoma Brain Mets delivers rapid MRI assessment and accurate, consistent analysis. With near-real-time study processing*, human expert-level performance*, and lesion identification as small as 1mm3 isotropic*, Neosoma is a best-in-class solution for clinical practice.

Technology That Reflects Reality
Brain mets lesions appear in many locations and often in numerous quantities, complicating assessment at a point in time, and especially over time as patients live longer.
Neosoma Brain Mets was engineered to reflect clinical reality, identifying lesions throughout the brain, and can track any number of identified lesions over time. Furthermore, Neosoma Brain Mets operates on routinely-acquired T1 post-contrast sequences, with no special acquisition protocols required.

Tools To Expedite Workflows
From "gestalt" graphs and reports providing critical summary information, to visual 3D longitudinal assessments, to our novel lesion quick-review wizard, Neosoma Brain Mets is built to expedite clinical case review without sacrificing empirical detail.

Interoperable
Easily import Neosoma Brain Mets lesion contours (GTVs) into radiation treatment and surgical planning software, such as Eclipse, MIM, Brainlab, Gamma Plan, and Stealth, among others.

Reimbursable
Two Category 3 CPT Codes allow departments to submit claims on a per-MRI-analysis basis, with or without a same-session diagnostic MRI.
More information is found on our Reimbursement page.
* Footnotes:
-
Study processing times based on internal Neosoma benchmarks.
-
Algorithm performance data from retrospective FDA performance testing, to be published.
